Melissa M. McLawhorn
Melissa M. McLawhorn has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Bonnie C. Carney
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA
3 shared publications Jeffrey W Shupp
Firefighters’ Burn and Surgical Research Laboratory, MedStar Health Research Institute , Washington, DC
3 shared publications- Jeffrey W. Shupp
Medstar Washington Hospital Center , 110 Irving St. NW, Washington, DC 20010
3 shared publications - Laura S. Johnson
Emory University School of Medicine and Grady Memorial Hospital, Department of Surgery , Atlanta, GA 30322
3 shared publications Lauren T Moffatt
Firefighters’ Burn and Surgical Research Laboratory, MedStar Health Research Institute , Washington, DC
3 shared publications- Taryn E. Travis
Department of Surgery, Georgetown University School of Medicine , Washington, DC 20010
3 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8168
Peripheral Blood Transcriptomic Profile Associated with Cutaneous Radiation Injury in Cancer Patients Undergoing Radiotherapy
The peripheral blood transcriptomic profile associated with clinically observed cutaneous radiation injury (CRI) during fractionated radiotherapy remains incompletely characterized. We analyzed blood transcriptomes from 22 adults receiving radiotherapy: 10 with CRI and 12 without radiation-related skin injury at blood collection. RNA was assayed using two-color Agilent microarrays. Variance filtering retained 12,251 probes that were evaluated using four complementary analyses: preranked Gene-Set Enrichment Analysis (GSEA) for ranked gene-set enrichment, Gene-Set Variation Analysis (GSVA) for sample-level gene-set scoring, weighted gene co-expression network analysis for co-expression structure, and differential expression analysis at the probe level. GSEA identified positive enrichment of interferon-γ response and E2F targets and negative enrichment of heme metabolism. Consistently, GSVA showed higher interferon-response, E2F-target, unfolded-protein-response, and cholesterol-homeostasis scores and lower angiogenesis, xenobiotic-metabolism, protein-secretion, hypoxia, and heme-metabolism scores in participants with CRI. Ten modular co-expression networks met the data-derived CRI-correlation prioritization criterion. Positively correlated networks were enriched for negative regulation of response to wounding and complement/coagulation cascades. Intramodular connectivity and sample-level expression analyses prioritized KDM4C and PARPBP as exploratory high-connectivity candidates, with both retaining top-10 connectivity in 95.5% of leave-one-out iterations. Exploratory differential expression analysis identified 1842 probes, comprising 585 upregulated and 1257 downregulated probes in CRI. Genes mapped from downregulated probes were significantly enriched for ribosome, spliceosome, and oxidative phosphorylation pathways. Across complementary analytical frameworks, CRI was associated with a coherent peripheral blood profile characterized by interferon and cell-cycle enrichment; altered wound-response and complement/coagulation processes; reduced heme-metabolism, angiogenesis, and xenobiotic-metabolism scores; and downregulated transcripts involved in ribosomal function, RNA processing, and mitochondrial energy metabolism. Although the cross-sectional design and later sampling of CRI participants precluded full separation of CRI-associated differences from treatment-time and cumulative-exposure effects, these findings extend the molecular characterization of CRI and identify pathways and high-connectivity candidates for longitudinal assessment of reproducibility, temporal dynamics, and potential diagnostic or predictive relevance.
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8168
Open AccessPeripheral Blood Transcriptomic Profile Associated with Cutaneous Radiation Injury in Cancer Patients Undergoing Radiotherapy
The peripheral blood transcriptomic profile associated with clinically observed cutaneous radiation injury (CRI) during fractionated radiotherapy remains incompletely characterized. We analyzed blood transcriptomes from 22 adults receiving radiotherapy: 10 with CRI and 12 without radiation-related skin injury at blood collection. RNA was assayed using two-color Agilent microarrays. Variance filtering retained 12,251 probes that were evaluated using four complementary analyses: preranked Gene-Set Enrichment Analysis (GSEA) for ranked gene-set enrichment, Gene-Set Variation Analysis (GSVA) for sample-level gene-set scoring, weighted gene co-expression network analysis for co-expression structure, and differential expression analysis at the probe level. GSEA identified positive enrichment of interferon-γ response and E2F targets and negative enrichment of heme metabolism. Consistently, GSVA showed higher interferon-response, E2F-target, unfolded-protein-response, and cholesterol-homeostasis scores and lower angiogenesis, xenobiotic-metabolism, protein-secretion, hypoxia, and heme-metabolism scores in participants with CRI. Ten modular co-expression networks met the data-derived CRI-correlation prioritization criterion. Positively correlated networks were enriched for negative regulation of response to wounding and complement/coagulation cascades. Intramodular connectivity and sample-level expression analyses prioritized KDM4C and PARPBP as exploratory high-connectivity candidates, with both retaining top-10 connectivity in 95.5% of leave-one-out iterations. Exploratory differential expression analysis identified 1842 probes, comprising 585 upregulated and 1257 downregulated probes in CRI. Genes mapped from downregulated probes were significantly enriched for ribosome, spliceosome, and oxidative phosphorylation pathways. Across complementary analytical frameworks, CRI was associated with a coherent peripheral blood profile characterized by interferon and cell-cycle enrichment; altered wound-response and complement/coagulation processes; reduced heme-metabolism, angiogenesis, and xenobiotic-metabolism scores; and downregulated transcripts involved in ribosomal function, RNA processing, and mitochondrial energy metabolism. Although the cross-sectional design and later sampling of CRI participants precluded full separation of CRI-associated differences from treatment-time and cumulative-exposure effects, these findings extend the molecular characterization of CRI and identify pathways and high-connectivity candidates for longitudinal assessment of reproducibility, temporal dynamics, and potential diagnostic or predictive relevance.
- 19 August 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (6) , 1882-1893
TMAO Correlates with Transcriptomic Signatures of Leukocyte Activation and Systemic Inflammation Following Burn Injury
Background: Severe burn injury induces gastrointestinal dysfunction and bacterial dysbiosis, yet the systemic impact of altered bacterial metabolites remains poorly understood. We assessed whether changes in plasma levels of trimethylamine N-oxide (TMAO), a gut-derived metabolite, have a relationship with changes in the whole blood transcriptomic profile following burn injury. Methods: Using previously harvested plasma from 67 burn patients, we quantified circulatory levels of TMAO via ELISA. To assess TMAO’s impact on the blood transcriptome, we applied a linear model to previously published whole blood microarray data from a subset of these patients (n = 22) with paired TMAO measurements. Results: While initial TMAO levels were comparable across small and larger burns, concentrations significantly increased 24-36 h post-admission in patients with >10% total body surface area (TBSA) burns, independent of age or sex. Elevated TMAO positively correlated with both burn size and Baux score. Furthermore, transcriptomic analysis revealed that high TMAO levels were strongly associated with the enrichment of inflammatory and leukocyte activation pathways, despite a lack of association between TMAO levels and imputed fractions of immune cells. Conclusion: Burn injury is associated with a delayed, severity-dependent elevation in circulating TMAO. This increase in TMAO correlates with transcriptomic signatures of robust immune activation and systemic inflammation, suggesting that targeting the gut microbiome and its metabolites may offer a novel therapeutic avenue to address post-burn inflammatory complications.
- 19 August 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (6) , 1882-1893
TMAO Correlates with Transcriptomic Signatures of Leukocyte Activation and Systemic Inflammation Following Burn Injury
Background: Severe burn injury induces gastrointestinal dysfunction and bacterial dysbiosis, yet the systemic impact of altered bacterial metabolites remains poorly understood. We assessed whether changes in plasma levels of trimethylamine N-oxide (TMAO), a gut-derived metabolite, have a relationship with changes in the whole blood transcriptomic profile following burn injury. Methods: Using previously harvested plasma from 67 burn patients, we quantified circulatory levels of TMAO via ELISA. To assess TMAO’s impact on the blood transcriptome, we applied a linear model to previously published whole blood microarray data from a subset of these patients (n = 22) with paired TMAO measurements. Results: While initial TMAO levels were comparable across small and larger burns, concentrations significantly increased 24-36 h post-admission in patients with >10% total body surface area (TBSA) burns, independent of age or sex. Elevated TMAO positively correlated with both burn size and Baux score. Furthermore, transcriptomic analysis revealed that high TMAO levels were strongly associated with the enrichment of inflammatory and leukocyte activation pathways, despite a lack of association between TMAO levels and imputed fractions of immune cells. Conclusion: Burn injury is associated with a delayed, severity-dependent elevation in circulating TMAO. This increase in TMAO correlates with transcriptomic signatures of robust immune activation and systemic inflammation, suggesting that targeting the gut microbiome and its metabolites may offer a novel therapeutic avenue to address post-burn inflammatory complications.
- 28 July 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (6) , 1778-1790
Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS)
Severe burn injury results in a profound hypermetabolic state that complicates management and recovery. Oxandrolone has historically been used to help attenuate this response, but its withdrawal from the United States (US) market has led to increased use of alternative anabolic agents such as testosterone and human growth hormone (HGH). However, studies comparing the efficacy and safety between these alternative anabolic agents in adult burn patients remain limited. In this multicenter study, patients were stratified based on if they received testosterone, oxandrolone, HGH, or no anabolic supplementation. Baseline characteristics and clinical outcomes were analyzed with analysis of variance and Chi-square testing as appropriate. Propensity score matching was used to adjust for baseline differences in injury severity and patient characteristics. 813 patients who sustained major burn injuries between June 2022 and June 2025 across 12 verified US burn centers were analyzed. Anabolic supplementation was not associated with improved inpatient weight maintenance when compared with no anabolic supplementation (P = .064), nor with differences in median weight change. Patients receiving anabolic therapy experienced longer hospital and intensive care unit stays (P = .026). Overall mortality did not differ between treated and untreated patients (P = .885); however, mortality was higher among patients treated with oxandrolone compared with testosterone (P = .001). Anabolic therapy was associated with higher rates of venous thromboembolic events (P = .019). These findings underscore that optimizing anabolic therapy will require balancing efficacy, safety, and economic considerations, with a focus on long-term functional outcomes beyond initial hospital stay.
- 28 July 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (6) , 1778-1790
Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS)
Severe burn injury results in a profound hypermetabolic state that complicates management and recovery. Oxandrolone has historically been used to help attenuate this response, but its withdrawal from the United States (US) market has led to increased use of alternative anabolic agents such as testosterone and human growth hormone (HGH). However, studies comparing the efficacy and safety between these alternative anabolic agents in adult burn patients remain limited. In this multicenter study, patients were stratified based on if they received testosterone, oxandrolone, HGH, or no anabolic supplementation. Baseline characteristics and clinical outcomes were analyzed with analysis of variance and Chi-square testing as appropriate. Propensity score matching was used to adjust for baseline differences in injury severity and patient characteristics. 813 patients who sustained major burn injuries between June 2022 and June 2025 across 12 verified US burn centers were analyzed. Anabolic supplementation was not associated with improved inpatient weight maintenance when compared with no anabolic supplementation (P = .064), nor with differences in median weight change. Patients receiving anabolic therapy experienced longer hospital and intensive care unit stays (P = .026). Overall mortality did not differ between treated and untreated patients (P = .885); however, mortality was higher among patients treated with oxandrolone compared with testosterone (P = .001). Anabolic therapy was associated with higher rates of venous thromboembolic events (P = .019). These findings underscore that optimizing anabolic therapy will require balancing efficacy, safety, and economic considerations, with a focus on long-term functional outcomes beyond initial hospital stay.
- 11 March 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (4) , 708-724
Lessons Learned Evaluating Ablative Fractional CO2 Laser for Burn-Related Donor Site Scars
Hypertrophic scar (HTS) remains a comorbidity of burn injury, often requiring split-thickness skin grafting (STSG) and resulting in symptomatic HTS at grafted sites and STSG donor sites (DS). Literature supports the use of ablative fractional CO2 laser (FLSR) to treat HTS, however many trials lack control sites and tissue-level examinations. Given the widespread adoption of FLSR for HTS, delegation of non-treated scar sites for the sake of randomized controlled trials (RCT) is troubling for many clinicians. We trialed using STSG DS scars for randomization rather than withholding FLSR from HTS at grafted sites. Patients (n = 20) were treated for DS scar with FLSR. DS scars were randomized and treated with either 6 FLSR treatments, follow-ups, and standard of care (SOC) or SOC only. Prior to treatment, DS skin and normal skin (NS) were evaluated for trans-epidermal water loss (TEWL), melanin index (MI), elasticity, and erythema. Serial biopsies were analyzed for epidermal thickness, rete ridge ratio (RRR), and papillary dermal cellularity. All sites, including a separate burn scar (BS) site, were evaluated using the patient and observer scar assessment scale (POSAS) -observer (-O), -patient (-P), Vancouver Scar Scale (VSS), and an institutional Scar Comparison Scale (SCS). Prior to treatment, the DS control (DS C), DS treated (DS T), and BS sites were hyperpigmented compared to normal skin. BS was less elastic than all other sites and had increased TEWL compared to normal skin. DS skin had increased cellularity, decreased rete ridge ratios, and increased epidermal thickness compared to NS. Clinician observers and patients perceived the BS site as more severe versus DS skin through the POSAS-O, POSAS-P, and VSS. Over time, DS C and DS T sites were not different in TEWL, elasticity, erythema, MI, cellularity, RRR, epidermal thickness, POSAS-O scores, POSAS-P scores, VSS scores, or SCS scores. Over time, burn scar did not change in TEWL, elasticity, erythema, MI, POSAS-O scores, POSAS-P scores, and VSS scores. Decreased SCS scores within the DS C, DS T, and BS sites indicated patient-perceived improvement in all scars throughout the study time course. NS and DS skin possess inherent physiological differences, though not to the degree of burn scars vs. NS. FLSR may not alter the rate of maturation and remodeling of DS skin compared to current SOC. While improvement in scar assessment was observed in laser-treated BS HTS, no specific control for these sites was analyzed. Due to differences in the pathophysiology of HTS formation at grafted and donor sites, the STSG DS may not be an adequate substitute for BS HTS when designing RCTs to evaluate the effect of FLSR. Prior studies evaluating the use of FLSR in burn-related HTS consist of low-powered clinical trials or case studies without control sites or tissue-level examinations, prompting the design of an RCT in DS scars. However, this scar type may not be suitable for this study design. Future work should extend to extra-cellular matrix morphology and transcriptomics of donor site and burn scar healing to better understand the effects of laser treatment.
- 11 March 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (4) , 708-724
Lessons Learned Evaluating Ablative Fractional CO2 Laser for Burn-Related Donor Site Scars
Hypertrophic scar (HTS) remains a comorbidity of burn injury, often requiring split-thickness skin grafting (STSG) and resulting in symptomatic HTS at grafted sites and STSG donor sites (DS). Literature supports the use of ablative fractional CO2 laser (FLSR) to treat HTS, however many trials lack control sites and tissue-level examinations. Given the widespread adoption of FLSR for HTS, delegation of non-treated scar sites for the sake of randomized controlled trials (RCT) is troubling for many clinicians. We trialed using STSG DS scars for randomization rather than withholding FLSR from HTS at grafted sites. Patients (n = 20) were treated for DS scar with FLSR. DS scars were randomized and treated with either 6 FLSR treatments, follow-ups, and standard of care (SOC) or SOC only. Prior to treatment, DS skin and normal skin (NS) were evaluated for trans-epidermal water loss (TEWL), melanin index (MI), elasticity, and erythema. Serial biopsies were analyzed for epidermal thickness, rete ridge ratio (RRR), and papillary dermal cellularity. All sites, including a separate burn scar (BS) site, were evaluated using the patient and observer scar assessment scale (POSAS) -observer (-O), -patient (-P), Vancouver Scar Scale (VSS), and an institutional Scar Comparison Scale (SCS). Prior to treatment, the DS control (DS C), DS treated (DS T), and BS sites were hyperpigmented compared to normal skin. BS was less elastic than all other sites and had increased TEWL compared to normal skin. DS skin had increased cellularity, decreased rete ridge ratios, and increased epidermal thickness compared to NS. Clinician observers and patients perceived the BS site as more severe versus DS skin through the POSAS-O, POSAS-P, and VSS. Over time, DS C and DS T sites were not different in TEWL, elasticity, erythema, MI, cellularity, RRR, epidermal thickness, POSAS-O scores, POSAS-P scores, VSS scores, or SCS scores. Over time, burn scar did not change in TEWL, elasticity, erythema, MI, POSAS-O scores, POSAS-P scores, and VSS scores. Decreased SCS scores within the DS C, DS T, and BS sites indicated patient-perceived improvement in all scars throughout the study time course. NS and DS skin possess inherent physiological differences, though not to the degree of burn scars vs. NS. FLSR may not alter the rate of maturation and remodeling of DS skin compared to current SOC. While improvement in scar assessment was observed in laser-treated BS HTS, no specific control for these sites was analyzed. Due to differences in the pathophysiology of HTS formation at grafted and donor sites, the STSG DS may not be an adequate substitute for BS HTS when designing RCTs to evaluate the effect of FLSR. Prior studies evaluating the use of FLSR in burn-related HTS consist of low-powered clinical trials or case studies without control sites or tissue-level examinations, prompting the design of an RCT in DS scars. However, this scar type may not be suitable for this study design. Future work should extend to extra-cellular matrix morphology and transcriptomics of donor site and burn scar healing to better understand the effects of laser treatment.
- 11 December 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients
Burn injury results in hypercoagulability and an increased venous thromboembolism risk. However, the most effective chemoprophylaxis for burn-injured patients has yet to be elucidated. Therefore, this study aims to identify the safety and efficacy of a burn center’s venous thromboembolism protocol modification, which increased the dose of enoxaparin from 40 mg daily to 40mg twice daily with peak anti-Xa level adjustments. It was hypothesized that this change would not increase bleeding complications and would decrease venous thromboembolism rates. All adult, burn-injured patients admitted to a regional burn center were retrospectively reviewed 1 year before and after the implementation of this protocol modification. There were no differences in demographics, injury characteristics, or hospital length of stay between the pre- (n = 432) and postprotocol modification (n = 407) groups. Bleeding complications did not increase in the postprotocol group, including intraoperative blood loss (50 vs 25cc), the total number of transfusions (9.0 vs 6.0 units), and GI bleeding events (0.7 vs 0.2%) (all P > .05). Most patients receiving enoxaparin 40 mg twice daily achieved an initial therapeutic level based on peak anti-Xa measurements (46.5%), yet the rate of venous thromboembolisms between pre- and postprotocol groups was not statistically different (1.4 vs 0.7%, P = .5072). Factors associated with an initial sub- or supratherapeutic peak anti-Xa level were percent total body surface area, weight, body mass index, and creatinine clearance. Overall, this study demonstrated that a higher dose of enoxaparin (40 mg twice daily) with peak anti-Xa level adjustments was safe in burn-injured patients and necessary to obtain therapeutic levels of chemoprophylaxis.
- 11 December 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Enoxaparin 40 mg Twice Daily With Peak Anti-Xa Adjustments Is Safe and Necessary to Achieve Therapeutic Chemoprophylaxis in Burn-Injured Patients
Burn injury results in hypercoagulability and an increased venous thromboembolism risk. However, the most effective chemoprophylaxis for burn-injured patients has yet to be elucidated. Therefore, this study aims to identify the safety and efficacy of a burn center’s venous thromboembolism protocol modification, which increased the dose of enoxaparin from 40 mg daily to 40mg twice daily with peak anti-Xa level adjustments. It was hypothesized that this change would not increase bleeding complications and would decrease venous thromboembolism rates. All adult, burn-injured patients admitted to a regional burn center were retrospectively reviewed 1 year before and after the implementation of this protocol modification. There were no differences in demographics, injury characteristics, or hospital length of stay between the pre- (n = 432) and postprotocol modification (n = 407) groups. Bleeding complications did not increase in the postprotocol group, including intraoperative blood loss (50 vs 25cc), the total number of transfusions (9.0 vs 6.0 units), and GI bleeding events (0.7 vs 0.2%) (all P > .05). Most patients receiving enoxaparin 40 mg twice daily achieved an initial therapeutic level based on peak anti-Xa measurements (46.5%), yet the rate of venous thromboembolisms between pre- and postprotocol groups was not statistically different (1.4 vs 0.7%, P = .5072). Factors associated with an initial sub- or supratherapeutic peak anti-Xa level were percent total body surface area, weight, body mass index, and creatinine clearance. Overall, this study demonstrated that a higher dose of enoxaparin (40 mg twice daily) with peak anti-Xa level adjustments was safe in burn-injured patients and necessary to obtain therapeutic levels of chemoprophylaxis.
- Open Access
- 11 July 2024
- Published by MDPI AG in Electronics
- Vol. 13 (14) , 2713
Initial Development and Analysis of a Context-Aware Burn Resuscitation Decision-Support Algorithm
Burn patients require high-volume intravenous resuscitation with the goal of restoring global tissue perfusion to make up for burn-induced loss of fluid from the vasculature. Clinical standards of burn resuscitation are predominantly based on urinary output, which is not context-aware because it is not a trustworthy indicator of tissue perfusion. This paper investigates the initial development and analysis of a context-aware decision-support algorithm for burn resuscitation. In this context, we hypothesized that the use of a more context-aware surrogate of tissue perfusion may enhance the efficacy of burn resuscitation in normalizing cardiac output. Toward this goal, we exploited the arterial pulse wave analysis to discover novel surrogates of cardiac output. Then, we developed the cardiac output-enabled burn resuscitation decision-support (CaRD) algorithm. Using experimental data collected from animals undergoing burn injury and resuscitation, we conducted an initial evaluation and analysis of the CaRD algorithm in comparison with the commercially available Burn NavigatorTM algorithm. Combining a surrogate of cardiac output with urinary output in the CaRD algorithm has the potential to improve the efficacy of burn resuscitation. However, the improvement achieved in this work was only marginal, which is likely due to the suboptimal tuning of the CaRD algorithm with the limited available dataset. In this way, the results showed both promise and challenges that are crucial to future algorithm development.
- 11 July 2024
- Published by MDPI AG in Electronics
- Vol. 13 (14) , 2713
Open AccessInitial Development and Analysis of a Context-Aware Burn Resuscitation Decision-Support Algorithm
Burn patients require high-volume intravenous resuscitation with the goal of restoring global tissue perfusion to make up for burn-induced loss of fluid from the vasculature. Clinical standards of burn resuscitation are predominantly based on urinary output, which is not context-aware because it is not a trustworthy indicator of tissue perfusion. This paper investigates the initial development and analysis of a context-aware decision-support algorithm for burn resuscitation. In this context, we hypothesized that the use of a more context-aware surrogate of tissue perfusion may enhance the efficacy of burn resuscitation in normalizing cardiac output. Toward this goal, we exploited the arterial pulse wave analysis to discover novel surrogates of cardiac output. Then, we developed the cardiac output-enabled burn resuscitation decision-support (CaRD) algorithm. Using experimental data collected from animals undergoing burn injury and resuscitation, we conducted an initial evaluation and analysis of the CaRD algorithm in comparison with the commercially available Burn NavigatorTM algorithm. Combining a surrogate of cardiac output with urinary output in the CaRD algorithm has the potential to improve the efficacy of burn resuscitation. However, the improvement achieved in this work was only marginal, which is likely due to the suboptimal tuning of the CaRD algorithm with the limited available dataset. In this way, the results showed both promise and challenges that are crucial to future algorithm development.
- Open Access
- 14 October 2023
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 45 (1) , 70-79
Comparison of Rapid-, Kaolin-, and Native-TEG Parameters in Burn Patient Cohorts With Acute Burn-induced Coagulopathy and Abnormal Fibrinolytic Function
Although use of thromboelastography (TEG) to diagnose coagulopathy and guide clinical decision-making is increasing, relative performance of different TEG methods has not been well-defined. Rapid-TEG (rTEG), kaolin-TEG (kTEG), and native-TEG (nTEG) were performed on blood samples from burn patients presenting to a regional center from admission to 21 days. Patients were categorized by burn severity, mortality, and fibrinolytic phenotypes (Shutdown [SD], Physiologic [PHYS], and Hyperfibrinolytic [HF]). Manufacturer ranges and published TEG cutoffs were examined. Concordance correlations (Rc) of TEG parameters (R, α-angle, maximum amplitude [MA], LY30) measured agreement and Cohen’s Kappa (κ) determined interclass reliability. Patients (n = 121) were mostly male (n = 84; 69.4%), with median age 40 years, median TBSA burn 13%, and mortality 17% (n = 21). Severe burns (≥40% TBSA) were associated with lower admission α-angle for rTEG (P = .03) and lower MA for rTEG (P = .02) and kTEG (P = .01). MA was lower in patients who died (nTEG, P = .04; kTEG, P = .02; rTEG, P = .003). Admission HF was associated with increased mortality (OR, 10.45; 95% CI, 2.54–43.31, P = .001) on rTEG only. Delayed SD was associated with mortality using rTEG and nTEG (OR 9.46; 95% CI, 1.96–45.73; P = .005 and OR, 6.91; 95% CI, 1.35–35.48; P = .02). Admission TEGs showed poor agreement on R-time (Rc, 0.00–0.56) and α-angle (0.40 to 0.55), and moderate agreement on MA (0.67–0.81) and LY30 (0.72–0.93). Interclass reliability was lowest for R-time (κ, −0.07 to 0.01) and α-angle (−0.06 to 0.17) and highest for MA (0.22-0.51) and LY30 (0.29-0.49). Choice of TEG method may impact clinical decision-making. rTEG appeared most sensitive in parameter-specific associations with injury severity, abnormal fibrinolysis, and mortality.
- 14 October 2023
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 45 (1) , 70-79
Open AccessComparison of Rapid-, Kaolin-, and Native-TEG Parameters in Burn Patient Cohorts With Acute Burn-induced Coagulopathy and Abnormal Fibrinolytic Function
Although use of thromboelastography (TEG) to diagnose coagulopathy and guide clinical decision-making is increasing, relative performance of different TEG methods has not been well-defined. Rapid-TEG (rTEG), kaolin-TEG (kTEG), and native-TEG (nTEG) were performed on blood samples from burn patients presenting to a regional center from admission to 21 days. Patients were categorized by burn severity, mortality, and fibrinolytic phenotypes (Shutdown [SD], Physiologic [PHYS], and Hyperfibrinolytic [HF]). Manufacturer ranges and published TEG cutoffs were examined. Concordance correlations (Rc) of TEG parameters (R, α-angle, maximum amplitude [MA], LY30) measured agreement and Cohen’s Kappa (κ) determined interclass reliability. Patients (n = 121) were mostly male (n = 84; 69.4%), with median age 40 years, median TBSA burn 13%, and mortality 17% (n = 21). Severe burns (≥40% TBSA) were associated with lower admission α-angle for rTEG (P = .03) and lower MA for rTEG (P = .02) and kTEG (P = .01). MA was lower in patients who died (nTEG, P = .04; kTEG, P = .02; rTEG, P = .003). Admission HF was associated with increased mortality (OR, 10.45; 95% CI, 2.54–43.31, P = .001) on rTEG only. Delayed SD was associated with mortality using rTEG and nTEG (OR 9.46; 95% CI, 1.96–45.73; P = .005 and OR, 6.91; 95% CI, 1.35–35.48; P = .02). Admission TEGs showed poor agreement on R-time (Rc, 0.00–0.56) and α-angle (0.40 to 0.55), and moderate agreement on MA (0.67–0.81) and LY30 (0.72–0.93). Interclass reliability was lowest for R-time (κ, −0.07 to 0.01) and α-angle (−0.06 to 0.17) and highest for MA (0.22-0.51) and LY30 (0.29-0.49). Choice of TEG method may impact clinical decision-making. rTEG appeared most sensitive in parameter-specific associations with injury severity, abnormal fibrinolysis, and mortality.
- Open Access
- 23 March 2022
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 43 (Supplement) , S42-S43
61 A Burn Center’s Experience with COVID-19 Positive Burn Patients
The emergence of SARS-COV-2 and the COVID-19 pandemic has complicated the presentation, treatment, and prognosis of all types of patients. Further characterization and analysis of how concomitant COVID-19 infection impacts different patient populations is important for improving treatment strategies. Patients with burn injures often require ICU-level care, mechanical ventilation, and extensive surgical intervention. Concomitant COVID-19 infection in this population presents a new challenge to clinical teams. The purpose of this project is to compare COVID-19 positive burn patients treated at a regional burn center with those that are not. Following IRB approval, our institution’s burn registry was queried from March 2020-June 2021. Data on demographics, injury circumstances, COVID-19 status, and outcomes were collected. Continuous variables were nonparametric and\compared using Mann-Whitney U test. Categorical variables were compared using Chi-squared with Fischer’s Exact test, where appropriate. Of the 622 patients admitted at our institution, 19 tested positive for COVID-19 during their hospitalization. Demographic and injury information is reported in Table 1. There were statistically significant differences between the COVID-19 positive and negative groups in regard to race and presence of inhalation injury (p=0.0002, p=0.0002). The TBSA burned was slightly higher in the COVID-19 positive group (9.1 vs 6.7%). COVID-19 positive patients spent more time ventilated (48±32.5 vs.12.2 ± 16.2 days, p=0.0035**) and had both longer ICU (42.71±37.41 vs 11.1±15.4 days, p=0.0175*) and hospital (26.32±32.14 vs 8.177±11.95 days, p< 0.0001***) lengths of stay (LOS). No COVID-19 positive patients died while 5% of the COVID-19 negative patients did. All outcomes were statistically significant. Despite similar TBSA injury burden and age breakdown, patients at our institution who tested positive for COVID-19 required more time on the ventilator and were hospitalized longer. People of color had a higher percentage of positive tests than their Caucasian counterparts. While mortality rates were higher in the COVID-19 negative cohort, morbidities associated with longer LOS must be considered.
- 23 March 2022
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 43 (Supplement) , S42-S43
Open Access61 A Burn Center’s Experience with COVID-19 Positive Burn Patients
The emergence of SARS-COV-2 and the COVID-19 pandemic has complicated the presentation, treatment, and prognosis of all types of patients. Further characterization and analysis of how concomitant COVID-19 infection impacts different patient populations is important for improving treatment strategies. Patients with burn injures often require ICU-level care, mechanical ventilation, and extensive surgical intervention. Concomitant COVID-19 infection in this population presents a new challenge to clinical teams. The purpose of this project is to compare COVID-19 positive burn patients treated at a regional burn center with those that are not. Following IRB approval, our institution’s burn registry was queried from March 2020-June 2021. Data on demographics, injury circumstances, COVID-19 status, and outcomes were collected. Continuous variables were nonparametric and\compared using Mann-Whitney U test. Categorical variables were compared using Chi-squared with Fischer’s Exact test, where appropriate. Of the 622 patients admitted at our institution, 19 tested positive for COVID-19 during their hospitalization. Demographic and injury information is reported in Table 1. There were statistically significant differences between the COVID-19 positive and negative groups in regard to race and presence of inhalation injury (p=0.0002, p=0.0002). The TBSA burned was slightly higher in the COVID-19 positive group (9.1 vs 6.7%). COVID-19 positive patients spent more time ventilated (48±32.5 vs.12.2 ± 16.2 days, p=0.0035**) and had both longer ICU (42.71±37.41 vs 11.1±15.4 days, p=0.0175*) and hospital (26.32±32.14 vs 8.177±11.95 days, p< 0.0001***) lengths of stay (LOS). No COVID-19 positive patients died while 5% of the COVID-19 negative patients did. All outcomes were statistically significant. Despite similar TBSA injury burden and age breakdown, patients at our institution who tested positive for COVID-19 required more time on the ventilator and were hospitalized longer. People of color had a higher percentage of positive tests than their Caucasian counterparts. While mortality rates were higher in the COVID-19 negative cohort, morbidities associated with longer LOS must be considered.
- 8 March 2019
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 40 (Supplement) , S229
506 A Burn Center’s Four Year Experience with a Cerium Nitrate & Silver Sulfadiazine Burn Cream
Morbidity from burn wound infection & sepsis remains high, but can be improved by early excision & grafting. However, certain situations preclude early surgery. In these cases, topical agents allow for staged excision. The combination of cerium nitrate & silver sulfadiazine (Cerium) is an inexpensive burn cream with broad antibacterial activity. It also forms an eschar over the wound that may promote reepithelialization. Methemoglobinemia (MetHba), an oft-cited side effect, is rare, but the compound is infrequently used worldwide. This is a retrospective cohort study investigating the effects of Cerium at a regional burn center. After IRB approval, patients admitted between 7/1/2014 & 7/1/2018 were screened to determine if they received Cerium. Data including demographics, burn injury & management, laboratory values & cerium application were extracted. Primary endpoints were time to surgery of Cerium-treated burns, reepithlialization & incidence of MetHba & its treatment. Of the 142 patients meeting inclusion criteria, the mean age was 56.3 & the majority were black (46%) males (67%). The most common etiologies were flame (43%), contact (25%) & scald (18%). Smoking was prevalent (28.5%). Mean TBSA was 9.9% with mean adjusted Baux score of 67.9 & APACHE II score of 10.8. 64.3% were admitted to the ICU & 10.7% had inhalation injury. Time to Cerium application was 1.67 days with 15.5 total doses received. Total TBSA treated with Cerium was 6.1% (4.5% full thickness, 1.6% partial thickness). Time to any surgery was 2.6 days whereas the time to surgery for areas treated with Cerium was 4.8 days. 10.7% of patients had treated wounds smaller than presentation at time of surgery. The mean pre-Cerium methemoglobin (MetHb) value was 1.2, while checks 12-36 h & 48-72 h post first application were 1.2 & 1.4, respectively. 9.8% developed MetHba levels >2.5%. All patients except 1 were asymptomatic. The symptomatic patient became hypoxic with MetHb of 9.4%, required reintubation, & was treated with Methylene Blue. At our center, Cerium is a well-tolerated medication with a minimal side-effect profile. Only one patient (0.7%) developed clinically significant MetHba requiring intervention. Reintubation in this patient was multifactorial as he had been extubated the same day & required frequent suctioning for copious, thick secretions, in addition to MetHba. Previous reports have described patients tolerating MetHb levels up to 31.8% without intubation. It can successfully be used to temporize burn wound excision & grafting, with our data supporting reepithelialization. Future work will study Cerium prospectively. Cerium cream is a topical dressing with few side effects which allows delayed burn excision & may improve tissue salvage.
- 8 March 2019
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 40 (Supplement) , S229
506 A Burn Center’s Four Year Experience with a Cerium Nitrate & Silver Sulfadiazine Burn Cream
Morbidity from burn wound infection & sepsis remains high, but can be improved by early excision & grafting. However, certain situations preclude early surgery. In these cases, topical agents allow for staged excision. The combination of cerium nitrate & silver sulfadiazine (Cerium) is an inexpensive burn cream with broad antibacterial activity. It also forms an eschar over the wound that may promote reepithelialization. Methemoglobinemia (MetHba), an oft-cited side effect, is rare, but the compound is infrequently used worldwide. This is a retrospective cohort study investigating the effects of Cerium at a regional burn center. After IRB approval, patients admitted between 7/1/2014 & 7/1/2018 were screened to determine if they received Cerium. Data including demographics, burn injury & management, laboratory values & cerium application were extracted. Primary endpoints were time to surgery of Cerium-treated burns, reepithlialization & incidence of MetHba & its treatment. Of the 142 patients meeting inclusion criteria, the mean age was 56.3 & the majority were black (46%) males (67%). The most common etiologies were flame (43%), contact (25%) & scald (18%). Smoking was prevalent (28.5%). Mean TBSA was 9.9% with mean adjusted Baux score of 67.9 & APACHE II score of 10.8. 64.3% were admitted to the ICU & 10.7% had inhalation injury. Time to Cerium application was 1.67 days with 15.5 total doses received. Total TBSA treated with Cerium was 6.1% (4.5% full thickness, 1.6% partial thickness). Time to any surgery was 2.6 days whereas the time to surgery for areas treated with Cerium was 4.8 days. 10.7% of patients had treated wounds smaller than presentation at time of surgery. The mean pre-Cerium methemoglobin (MetHb) value was 1.2, while checks 12-36 h & 48-72 h post first application were 1.2 & 1.4, respectively. 9.8% developed MetHba levels >2.5%. All patients except 1 were asymptomatic. The symptomatic patient became hypoxic with MetHb of 9.4%, required reintubation, & was treated with Methylene Blue. At our center, Cerium is a well-tolerated medication with a minimal side-effect profile. Only one patient (0.7%) developed clinically significant MetHba requiring intervention. Reintubation in this patient was multifactorial as he had been extubated the same day & required frequent suctioning for copious, thick secretions, in addition to MetHba. Previous reports have described patients tolerating MetHb levels up to 31.8% without intubation. It can successfully be used to temporize burn wound excision & grafting, with our data supporting reepithelialization. Future work will study Cerium prospectively. Cerium cream is a topical dressing with few side effects which allows delayed burn excision & may improve tissue salvage.